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Controversies in the Management
of Cysticercosis
Cysticercosis, an infection caused by larvae of
the pork tapeworm Taenia solium in human tis-
sues, is a common cause of neurologic disease in
most non-Muslim developing countries, where it
accounts for more than one-third of adult-onset
epilepsy cases (1). Cysticercosis is increasingly
diagnosed in patients in industrialized nations;
persons who have never left the United States as
well as visitors to disease-endemic regions are at
risk. Traditionally considered an exotic disease,
this infection now accounts for up to 2% of neuro-
logic/neurosurgical admissions in southern Cali-
fornia (2) and more than 1,000 cases per year in
the United States (3). Further away from disease-
endemic regions, an outbreak of cysticercosis
among orthodox Jews living in New York City
was reported after food was contaminated with
T. solium  eggs by immigrant cooks infected with
the pork tapeworm (4); these carriers may have
been completely unaware of their infections.
Neurocysticercosis has been reported in AIDS
patients, but immuno-suppression does not
appear to increase the incidence of this infection.
Once cysticercosis is diagnosed, treatment may
be necessary, but optimal therapy and particularly
the role of cestocidal drugs is controversial. In
this commentary, we discuss current options in
the treatment of established cysticercosis.
The clinical and pathologic features of neuro-
cysticercosis vary, depending on the inflam-matory
response around cysticerci, their number, size,
and location. The presence of viable, living cysti-
cerci in the central nervous system usually does
not cause symptoms (5). In contrast, inflammation
around degenerating cysticerci may have severe
consequences, including focal encephalitis, edema,
and vasculitis. The most frequent symptom is
epilepsy. However, neurocysticercosis can cause
a wide variety of clinical syndromes—from
chronic meningitis and cranial nerve palsies to
spinal infarction and symptoms due to either a
mass effect or, particularly in racemose disease,
raised intracranial pressure. Such variable clini-
cal features necessitate further investigations to
make a diagnosis before treatment.
The diagnosis may be made by excision biopsy
of subcutaneous cysticerci, which are found in 4%
to 25% of patients with neurocysticercosis (the
percentages are higher in Asia than in Latin
America). However, radiologic and serologic tests
are usually required for diagnosis unless biopsy
of a central nervous system lesion is possible.
Computed tomography visualizes living cysticerci
as hypodense lesions not enhanced with intra-
venous contrast; a small, hyperdense scolex may
be observed within a living cyst (6). Degenerating
cysticerci which are more often symptomatic are
isodense or hyperdense, and edematous inflam-
mation around them usually causes ring or nodu-
lar enhancement by intravenous contrast (5).
Magnetic resonance imaging provides detailed
images of living and degenerating cysticerci, as
seen in a heavily infected patient (Figure), but
may not detect calcified, destroyed cysticerci (3).
An immunoblot diagnostic test on serum has
been shown to have greater than 98% sensitivity
and specificity (7). However, in patients with sin-
gle ring-enhancing lesions, sensitivity falls to 60%
to 80%. Sensitivity is also reduced if cerebrospinal
fluid rather than serum immunoblot is used.
Figure. Magnetic resonance image of a patient with
neurocysticercosis demonstrating multiple cysticerci
within the brain.
The treatment of established neurocys-
ticercosis is controversial and probably depends
on the associated inflammatory reaction as well
as clinical and pathologic features. Symptomatic
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therapy with conventional anticonvulsant drugs
is indicated to control epilepsy. Symptoms often
result from self-limiting inflammation around a
degenerating cysticercus (3,5). Raised intracranial
pressure caused by this local reaction usually
responds to oral corticosteroids. Steroids have
been given chronically in occasional cases of per-
sistent intracranial inflammation. Surgery also
has a role: a ventriculoperitoneal shunt relieves
obstructive hydrocephalus, although shunt blockage
is common when the cerebrospinal fluid protein
is elevated. Because inflammation associated
with medical therapy may threaten vision, sur-
gery has been used to excise intraocular cysti-
cerci. Asymptomatic subcutaneous or intra-
muscular cysticerci do not require treatment.
Cestocidal therapy with praziquantel (50 mg/
kg/day tid orally for 14 days) or albendazole (15
mg/kg orally tid/bid for 8 to 15 days) accelerates
radiologic disappearance of viable intracranial
cysticerci. Albendazole may have slightly greater
efficacy and is generally less expensive than
praziquantel. Cestocidal treatment combined with
symptomatic care is associated with a good
clinical outcome (8,9). However, these nonran-
domized trials were not optimally controlled, and
a similarly benign clinical course has been
described after symptomatic treatment alone in
both adults (5) and children (10). Furthermore,
randomized placebo controlled trials with
selected patients have shown no clinical (11) or
radiologic (12,13) benefit from the addition of
cestocidal therapy to symptomatic care. A prob-
lem with cestocidal therapy is that it causes
influx of inflammatory cells around cysticerci,
which is often associated with transient clinical
deterioration (8). Rarely, this may be fatal in
heavy infections, despite administration of cor-
ticosteroids, a common practice to minimize
adverse effects (6). Although coadministering
corticosteroids reduces blood levels of praziquantel
and increases those of albendazole, these effects
do not appear to be relevant clinically. Therefore,
the immunologic basis has yet to be determined
for the inflammation around cysts when they die
or are killed by cestocidal treatment (14).
Although recommendations cannot yet be
definitive, available evidence suggests that via-
ble, intact cysticerci that cause epilepsy or other
symptoms can be treated with cestocidal therapy,
especially if they are causing mass effect. If
cestocidal treatment is instituted, there is no
reason to avoid the use of steroids. These should
always be administered before cestocidal therapy
is given to patients with multiple viable intra-
cranial cysticerci because the sudden and simul-
taneous death of these parasites would otherwise
cause inflammation, which can be fatal. In
contrast, when untreated patients have neurologic
symptoms and radiologic evidence of inflammation
around a degenerating cysticercus, the parasite
has probably already died, and cestocidal therapy is
unlikely to be of benefit. In such cases, an expec-
tant policy is reasonable: symptomatic therapy
alone for 6 to 12 weeks, unless the patient’s
condition worsens. A repeat computed tomography
scan then usually shows reduction in size or dis-
appearance of a degenerating cysticercus (12,13,15).
If improvement has not occurred, then empirical
cestocidal chemotherapy may be considered, and
possible alternative diagnoses such as tubercu-
losis should be entertained. Intracranial calci-
fications and lesions that show ring enhancement
on neuroimaging are not living parasites and
probably do not warrant cestocidal therapy.
This approach to cestocidal therapy is contro-
versial, and the results of at least one ongoing,
double-blind, randomized placebo-controlled trial
are keenly awaited. Even when the value of cesto-
cidal therapy is firmly established or refuted,
new antiinflammatory treatments will require
therapeutic approaches to be reevaluated. A
greater understanding of the pathogenesis of
this condition is a prerequisite to developing
effective therapy to control inflammation
around degenerating cysticerci.
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